Several vaccines against chikungunya fever have been developed and tested, and one has been recently licensed. We performed a meta-analysis to estimate the immunogenicity and safety of all chikungunya vaccines that have been progressed to clinical trial evaluation (VLA1553; mRNA-1388/VAL-181388; PXVX0317/VRC-CHKVLP059-00-VP; ChAdOx1 Chik; MV-CHIK). We included trials retrieved from MedLine, Scopus, and ClinicalTrials.gov. The outcomes were the rates of seroconversion/seroresponse and serious adverse events (SAEs) after the primary immunization course. We retrieved a total of 14 datasets, including >4000 participants. All candidate chikungunya vaccines were able to elicit an immunogenic response in ≥96% of vaccinated subjects, regardless of the vaccination schedule and platform used, and the seroconversion/seroresponse rates remained high 6 to 12 months after vaccination for most vaccines. Four of the five candidate vaccines showed a good overall safety profile (no data were available for ChAdOx1 Chik), with no significant increase in the risk of SAEs among the vaccinated, and a low absolute risk of product-related SAEs. Overall, the present findings support the potential use of the candidate vaccines for the prevention of chikungunya and the current indication for use in adult travelers to endemic regions of the licensed VLA 1553 vaccine. In order to extend chikungunya vaccination to a wider audience, further studies are needed on individuals from endemic countries and frail populations.

Rosso, A., Flacco, M.E., Cioni, G., Tiseo, M., Imperiali, G., Bianconi, A., et al. (2024). Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis. VACCINES, 12(9), 1-19 [10.3390/vaccines12090969].

Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis

Bianconi, Alessandro
Methodology
;
Fiore, Matteo
Formal Analysis
;
Manzoli, Lamberto
Ultimo
Writing – Original Draft Preparation
2024

Abstract

Several vaccines against chikungunya fever have been developed and tested, and one has been recently licensed. We performed a meta-analysis to estimate the immunogenicity and safety of all chikungunya vaccines that have been progressed to clinical trial evaluation (VLA1553; mRNA-1388/VAL-181388; PXVX0317/VRC-CHKVLP059-00-VP; ChAdOx1 Chik; MV-CHIK). We included trials retrieved from MedLine, Scopus, and ClinicalTrials.gov. The outcomes were the rates of seroconversion/seroresponse and serious adverse events (SAEs) after the primary immunization course. We retrieved a total of 14 datasets, including >4000 participants. All candidate chikungunya vaccines were able to elicit an immunogenic response in ≥96% of vaccinated subjects, regardless of the vaccination schedule and platform used, and the seroconversion/seroresponse rates remained high 6 to 12 months after vaccination for most vaccines. Four of the five candidate vaccines showed a good overall safety profile (no data were available for ChAdOx1 Chik), with no significant increase in the risk of SAEs among the vaccinated, and a low absolute risk of product-related SAEs. Overall, the present findings support the potential use of the candidate vaccines for the prevention of chikungunya and the current indication for use in adult travelers to endemic regions of the licensed VLA 1553 vaccine. In order to extend chikungunya vaccination to a wider audience, further studies are needed on individuals from endemic countries and frail populations.
2024
Rosso, A., Flacco, M.E., Cioni, G., Tiseo, M., Imperiali, G., Bianconi, A., et al. (2024). Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis. VACCINES, 12(9), 1-19 [10.3390/vaccines12090969].
Rosso, Annalisa; Flacco, Maria Elena; Cioni, Giovanni; Tiseo, Marco; Imperiali, Gianmarco; Bianconi, Alessandro; Fiore, Matteo; Calò, Giovanna Letizia...espandi
File in questo prodotto:
File Dimensione Formato  
Manzoli L Vaccines (Chikungunya) 2024.pdf

accesso aperto

Descrizione: Article
Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 590.93 kB
Formato Adobe PDF
590.93 kB Adobe PDF Visualizza/Apri
vaccines-12-00969-s001.zip

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 150.02 kB
Formato Zip File
150.02 kB Zip File Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/979803
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact